PF-AtlasClinical Trials › NCT03538301

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

ND-L02-s0201 · Phase 2

Registry ID
NCT03538301
Phase
Phase 2
Status
Completed
Drug / intervention
ND-L02-s0201 (Low Dose)
Sponsor
Nitto Denko Corporation
Start
2018-06-18
Enrollment
123
Locations
33

About this trial

A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

View NCT03538301 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT03538301 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.